Shares of Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) have been assigned an average recommendation of “Hold” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.00.
A number of brokerages recently issued reports on AVR. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a report on Wednesday, October 14th. Finally, Barclays raised shares of Anteris Technologies Global to a “hold” rating in a research report on Wednesday, October 7th.
Get Our Latest Stock Report on Anteris Technologies Global
Anteris Technologies Global Stock Down 5.5%
Shares of NASDAQ AVR opened at $5.86 on Friday. Anteris Technologies Global has a 52 week low of $3.30 and a 52 week high of $11.06. The firm’s fifty day moving average is $7.03 and its 200 day moving average is $7.38. The company has a market cap of $571.29 million, a price-to-earnings ratio of -3.64 and a beta of 2.02.
Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $2.75 million. Anteris Technologies Global had a negative net margin of 4,637.48% and a negative return on equity of 57.15%. Equities research analysts anticipate that Anteris Technologies Global will post -1.21 earnings per share for the current year.
Insider Activity at Anteris Technologies Global
In related news, major shareholder L1 Capital Pty Ltd bought 272,695 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were purchased at an average price of $7.18 per share, with a total value of $1,957,950.10. Following the purchase, the insider owned 6,358,271 shares of the company’s stock, valued at approximately $45,652,385.78. This trade represents a 4.48% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have bought 1,554,730 shares of company stock valued at $11,694,513. Company insiders own 4.50% of the company’s stock.
Hedge Funds Weigh In On Anteris Technologies Global
A number of institutional investors have recently bought and sold shares of AVR. BlackRock Inc. bought a new stake in shares of Anteris Technologies Global during the second quarter valued at approximately $56,846,000. ADAR1 Capital Management LLC grew its stake in Anteris Technologies Global by 205.9% in the first quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock worth $21,030,000 after purchasing an additional 2,550,355 shares during the period. Perceptive Advisors LLC raised its holdings in Anteris Technologies Global by 104.4% in the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after purchasing an additional 1,750,000 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Anteris Technologies Global in the second quarter worth $33,325,850. Finally, Affinity Asset Advisors LLC raised its holdings in Anteris Technologies Global by 87.5% in the first quarter. Affinity Asset Advisors LLC now owns 912,397 shares of the company’s stock worth $5,064,000 after purchasing an additional 425,713 shares in the last quarter.
About Anteris Technologies Global
Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.
Further Reading
- Five stocks we like better than Anteris Technologies Global
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
